Journal ArticleDOI
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
Matthias Oelke,Alexander Bachmann,Aurélien Descazeaud,Mark Emberton,Stavros Gravas,Martin C. Michel,James N'Dow,Jørgen Nordling,Jean J.M.C.H. de la Rosette +8 more
TLDR
The 2013 version of the European Association of Urology guidelines on the treatment and follow-up of male lower urinary tract symptoms (LUTS) provides practical guidance for the management of men experiencing LUTS.About:
This article is published in European Urology.The article was published on 2013-07-01. It has received 1060 citations till now. The article focuses on the topics: Lower urinary tract symptoms & Urinary retention.read more
Citations
More filters
Journal ArticleDOI
EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction ☆
Christian Gratzke,Alexander Bachmann,Aurélien Descazeaud,Marcus J. Drake,Stephan Madersbacher,Charalampos Mamoulakis,Matthias Oelke,Kari A.O. Tikkinen,Stavros Gravas +8 more
TL;DR: European Association of Urology guidelines for non-neurogenic male lower urinary tract symptoms (LUTS) are presented, able to distinguish between uncomplicated male LUTS and possible differential diagnoses and to evaluate baseline parameters for treatment.
Journal ArticleDOI
A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update
Jean Nicolas Cornu,Sascha Ahyai,Alexander Bachmann,Jean J.M.C.H. de la Rosette,Peter J. Gilling,Christian Gratzke,Kevin T. McVary,Giacomo Novara,Henry H. Woo,Stephan Madersbacher +9 more
TL;DR: A meta-analysis of available randomized controlled trials shows that HoLEP is associated with more favorable outcomes than M-TURP in published RCTs and needs to be refined to propose tailored surgical treatment for benign prostatic obstruction relief.
Journal ArticleDOI
A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with α-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Mauro Gacci,Giovanni Corona,Matteo Salvi,Linda Vignozzi,Kevin T. McVary,Steven A. Kaplan,Claus G. Roehrborn,Sergio Serni,Vincenzo Mirone,Marco Carini,Mario Maggi +10 more
TL;DR: It is suggested that PDE5-Is can significantly improve LUTS and erectile function in men with BPH and seem to be a promising treatment option for patients with LUTs secondary to BPH with or without ED.
Journal ArticleDOI
What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women
Arnav Agarwal,Leyla Eryuzlu,Rufus Cartwright,Kristian Thorlund,Teuvo L.J. Tammela,Gordon H. Guyatt,Anssi Auvinen,Kari A.O. Tikkinen,Kari A.O. Tikkinen +8 more
TL;DR: Urinary urgency was the most common troubling symptom in a large population-based study; however, for individuals, urgency incontinence was themost likely to be rated as bothersome.
Journal ArticleDOI
180-W XPS GreenLight Laser Vaporisation Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trial—The GOLIATH Study
Alexander Bachmann,Andrea Tubaro,Neil Barber,Frank C H d'Ancona,Gordon Muir,Ulrich Witzsch,Marc-Oliver Grimm,Joan Benejam,Jens-Uwe Stolzenburg,Antony C. P. Riddick,Sascha Pahernik,Herman Roelink,Filip Ameye,Christian Saussine,Franck Bruyère,Wolfgang Loidl,Tim Larner,Nirjan-Kumar Gogoi,Richard Hindley,Rolf Muschter,Andrew C. Thorpe,Nitin Shrotri,Stuart Graham,Moritz Hamann,Kurt Miller,Martin Schostak,Carlos Capitán,Helmut H. Knispel,J. Andrew Thomas +28 more
TL;DR: XPS was shown to be noninferior (comparable) to TURP in terms of IPSS, Qmax, and proportion of patients free of complications and PV and PVR were comparable between groups.
References
More filters
Journal ArticleDOI
The Influence of Finasteride on the Development of Prostate Cancer
Ian M. Thompson,Phyllis J. Goodman,Catherine M. Tangen,M. Scott Lucia,Gary J. Miller,Leslie G. Ford,Michael M. Lieber,R. Duane Cespedes,JN Atkins,Scott M. Lippman,Susie M. Carlin,Anne Ryan,Connie M. Szczepanek,John Crowley,Charles A. Coltman +14 more
TL;DR: Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
Journal ArticleDOI
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
John D. McConnell,Claus G. Roehrborn,Oliver Bautista,Gerald L. Andriole,Christopher M. Dixon,John W. Kusek,Herbert Lepor,Kevin T. McVary,Leroy M. Nyberg,Harry Clarke,E. David Crawford,Ananias C. Diokno,John P. Foley,Harris E. Foster,Stephen C. Jacobs,Steven A. Kaplan,Karl J. Kreder,Michael M. Lieber,M. Scott Lucia,Gary J. Miller,Mani Menon,Douglas F. Milam,Joe W. Ramsdell,Noah S. Schenkman,Kevin M. Slawin,Joseph A. Smith +25 more
TL;DR: Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone.
Journal ArticleDOI
2007 Guideline for the Management of Ureteral Calculi
Glenn M. Preminger,Hans Göran Tiselius,Dean G. Assimos,Peter Alken,A. Colin Buck,Michele Gallucci,Thomas Knoll,James E. Lingeman,Stephen Y. Nakada,Margaret S. Pearle,Kemal Sarica,Christian Türk,J. Stuart Wolf +12 more
TL;DR: This joint EAU/AUA Nephrolithiasis Guideline Panel performed a systematic review of the English language literature published since 1997 and a comprehensively analyzed outcomes data from the identified studies, dedicating this report to the memory of Dr. Joseph W. Segura whose vision, integrity, and perseverance led to the establishment of the first international guideline project.
Journal ArticleDOI
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
John D. McConnell,Reginald C. Bruskewitz,Patrick C. Walsh,Gerald L. Andriole,Michael M. Lieber,H.L. Holtgrewe,Peter C. Albertsen,Claus G. Roehrborn,J.C. Nickel,Daniel Z. Wang,Alice Taylor,Joanne Waldstreicher +11 more
TL;DR: Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the probability of surgery and acute urinary retention.
Journal ArticleDOI
Effect of dutasteride on the risk of prostate cancer.
Gerald L. Andriole,David G. Bostwick,Otis W. Brawley,Leonard G. Gomella,Michael Marberger,Francesco Montorsi,Curtis A. Pettaway,Teuvo L.J. Tammela,Claudio Teloken,Donald J. Tindall,Matthew C. Somerville,Timothy Wilson,Ivy L. Fowler,Roger S. Rittmaster +13 more
TL;DR: Over the course of the 4-year study period, dutasteride reduced the risk of incident prostate cancer detected on biopsy and improved the outcomes related to benign prostatic hyperplasia.
Related Papers (5)
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
John D. McConnell,Claus G. Roehrborn,Oliver Bautista,Gerald L. Andriole,Christopher M. Dixon,John W. Kusek,Herbert Lepor,Kevin T. McVary,Leroy M. Nyberg,Harry Clarke,E. David Crawford,Ananias C. Diokno,John P. Foley,Harris E. Foster,Stephen C. Jacobs,Steven A. Kaplan,Karl J. Kreder,Michael M. Lieber,M. Scott Lucia,Gary J. Miller,Mani Menon,Douglas F. Milam,Joe W. Ramsdell,Noah S. Schenkman,Kevin M. Slawin,Joseph A. Smith +25 more